DDInter1274 DDInter1763
Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Nefazodone {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Nefazodone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Nefazodone {u} (Compound) upregulates {v} (Gene) CDH3
CDH3 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Nefazodone {u} (Compound) downregulates {v} (Gene) CTGF
CTGF {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Nefazodone {u} (Compound) downregulates {v} (Gene) SDHB
SDHB {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Nefazodone {u} (Compound) causes {v} (Side Effect) Ecchymosis
Ecchymosis {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Nefazodone {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Nefazodone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Nefazodone {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) covaries with {v} (Gene) YRDC
YRDC {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Nefazodone {u} (Compound) upregulates {v} (Gene) CDH3
CDH3 {u} (Gene) is downregulated by {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Temsirolimus
Nefazodone may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Nefazodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Nefazodone (Compound) upregulates CDH3 (Gene) and CDH3 (Gene) is upregulated by Temsirolimus (Compound)
Nefazodone (Compound) downregulates CTGF (Gene) and CTGF (Gene) is upregulated by Temsirolimus (Compound)
Nefazodone (Compound) downregulates SDHB (Gene) and SDHB (Gene) is downregulated by Temsirolimus (Compound)
Nefazodone (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Temsirolimus (Compound)
Nefazodone may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Nefazodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Nefazodone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) covaries with YRDC (Gene) and YRDC (Gene) is downregulated by Temsirolimus (Compound)
Nefazodone (Compound) upregulates CDH3 (Gene) and CDH3 (Gene) is downregulated by kidney cancer (Disease) and kidney cancer (Disease) is treated by Temsirolimus (Compound)